Your browser doesn't support javascript.
loading
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
Law, Philip J; Sud, Amit; Mitchell, Jonathan S; Henrion, Marc; Orlando, Giulia; Lenive, Oleg; Broderick, Peter; Speedy, Helen E; Johnson, David C; Kaiser, Martin; Weinhold, Niels; Cooke, Rosie; Sunter, Nicola J; Jackson, Graham H; Summerfield, Geoffrey; Harris, Robert J; Pettitt, Andrew R; Allsup, David J; Carmichael, Jonathan; Bailey, James R; Pratt, Guy; Rahman, Thahira; Pepper, Chris; Fegan, Chris; von Strandmann, Elke Pogge; Engert, Andreas; Försti, Asta; Chen, Bowang; Filho, Miguel Inacio da Silva; Thomsen, Hauke; Hoffmann, Per; Noethen, Markus M; Eisele, Lewin; Jöckel, Karl-Heinz; Allan, James M; Swerdlow, Anthony J; Goldschmidt, Hartmut; Catovsky, Daniel; Morgan, Gareth J; Hemminki, Kari; Houlston, Richard S.
Afiliação
  • Law PJ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Sud A; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Mitchell JS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Henrion M; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Orlando G; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Lenive O; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Broderick P; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Speedy HE; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Johnson DC; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Kaiser M; Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
  • Weinhold N; Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, USA.
  • Cooke R; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Sunter NJ; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Jackson GH; Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Summerfield G; Department of Haematology, Queen Elizabeth Hospital, Gateshead, Newcastle upon Tyne, UK.
  • Harris RJ; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Pettitt AR; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Allsup DJ; Queens Centre for Haematology and Oncology, Castle Hill Hospital, Hull and East Yorkshire NHS Trust, UK.
  • Carmichael J; Queens Centre for Haematology and Oncology, Castle Hill Hospital, Hull and East Yorkshire NHS Trust, UK.
  • Bailey JR; Queens Centre for Haematology and Oncology, Castle Hill Hospital, Hull and East Yorkshire NHS Trust, UK.
  • Pratt G; Department of Haematology, Birmingham Heartlands Hospital, Birmingham, UK.
  • Rahman T; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Pepper C; Department of Haematology, School of Medicine, Cardiff University, Cardiff, UK.
  • Fegan C; Cardiff and Vale National Health Service Trust, Heath Park, Cardiff, UK.
  • von Strandmann EP; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • Engert A; Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • Försti A; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
  • Chen B; Centre for Primary Health Care Research, Lund University, Malmö, Sweden.
  • Filho MI; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
  • Thomsen H; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
  • Hoffmann P; Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany.
  • Noethen MM; Institute of Human Genetics, University of Bonn, Germany.
  • Eisele L; Division of Medical Genetics, Department of Biomedicine, University of Basel, Switzerland.
  • Jöckel KH; Institute of Human Genetics, University of Bonn, Germany.
  • Allan JM; Department of Genomics, Life &Brain Center, University of Bonn, Germany.
  • Swerdlow AJ; University of Duisburg-Essen, Essen, Germany.
  • Goldschmidt H; University of Duisburg-Essen, Essen, Germany.
  • Catovsky D; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
  • Morgan GJ; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
  • Hemminki K; Division of Breast Cancer Research, The Institute of Cancer Research, London, UK.
  • Houlston RS; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Sci Rep ; 7: 41071, 2017 01 23.
Article em En | MEDLINE | ID: mdl-28112199
ABSTRACT
B-cell malignancies (BCM) originate from the same cell of origin, but at different maturation stages and have distinct clinical phenotypes. Although genetic risk variants for individual BCMs have been identified, an agnostic, genome-wide search for shared genetic susceptibility has not been performed. We explored genome-wide association studies of chronic lymphocytic leukaemia (CLL, N = 1,842), Hodgkin lymphoma (HL, N = 1,465) and multiple myeloma (MM, N = 3,790). We identified a novel pleiotropic risk locus at 3q22.2 (NCK1, rs11715604, P = 1.60 × 10-9) with opposing effects between CLL (P = 1.97 × 10-8) and HL (P = 3.31 × 10-3). Eight established non-HLA risk loci showed pleiotropic associations. Within the HLA region, Ser37 + Phe37 in HLA-DRB1 (P = 1.84 × 10-12) was associated with increased CLL and HL risk (P = 4.68 × 10-12), and reduced MM risk (P = 1.12 × 10-2), and Gly70 in HLA-DQB1 (P = 3.15 × 10-10) showed opposing effects between CLL (P = 3.52 × 10-3) and HL (P = 3.41 × 10-9). By integrating eQTL, Hi-C and ChIP-seq data, we show that the pleiotropic risk loci are enriched for B-cell regulatory elements, as well as an over-representation of binding of key B-cell transcription factors. These data identify shared biological pathways influencing the development of CLL, HL and MM. The identification of these risk loci furthers our understanding of the aetiological basis of BCMs.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Leucemia Linfocítica Crônica de Células B / Estudo de Associação Genômica Ampla / Pleiotropia Genética / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin / Leucemia Linfocítica Crônica de Células B / Estudo de Associação Genômica Ampla / Pleiotropia Genética / Mieloma Múltiplo Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article